Innovation in bone healing and tissue repair
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.

Kuros has developed a pipeline of clinical and preclinical programmes at various stages of development and generated significant data in a number of indications and applications. The most advanced programmes are targeting commercially attractive opportunities in certain segments of the tissue repair and regeneration space, notably sealants and orthobiologics. In addition to many years of substantial preclinical work, Kuros Biosurgery has now enrolled over 600 patients in multi-national clinical trials, generating promising safety and efficacy in a number of indications.

Latest News
14 Dec 17
Kuros Biosciences Announces Management Succession
Kuros announced today the appointment of Michael Grau as Chief Financial Officer (CFO) effective February 1, 2018. Michael Grau succeeds Harry Welten, who will step down as CFO on February 1, 2018 to focus on his board roles and... READ MORE


28 Nov 17
Kuros Biosciences’ Chief Medical Officer to Retire
Kuros announced today that its Chief Medical Officer, Dr. Virginia Jamieson, has reached retirement age and will retire from full-time employment with effect as of May 31, 2018. Her succession will be announced in due course. ... READ MORE


Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Executive Committee
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    MagnetOs
    Spinal fusion
    KUR-113
    MagnetOs
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Surface Science Technology
  3. Synthetic Cross-Linking Technology
  4. Fibrin-Based
  5. Immune Modulation
  6. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.

Kuros has developed a pipeline of clinical and preclinical programmes at various stages of development and generated significant data in a number of indications and applications. The most advanced programmes are targeting commercially attractive opportunities in certain segments of the tissue repair and regeneration space, notably sealants and orthobiologics. In addition to many years of substantial preclinical work, Kuros Biosurgery has now enrolled over 600 patients in multi-national clinical trials, generating promising safety and efficacy in a number of indications.

Latest News
14 Dec 17
Kuros Biosciences Announces Management Succession
Kuros announced today the appointment of Michael Grau as Chief Financial Officer (CFO) effective February 1, 2018. Michael Grau succeeds Harry Welten, who will step down as CFO on February 1, 2018 to focus on his board roles and... READ MORE


28 Nov 17
Kuros Biosciences’ Chief Medical Officer to Retire
Kuros announced today that its Chief Medical Officer, Dr. Virginia Jamieson, has reached retirement age and will retire from full-time employment with effect as of May 31, 2018. Her succession will be announced in due course. ... READ MORE